Zacks.com on MSN1d
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
bovnews1d
Analysts Predict a $35 Target for Catalyst Pharmaceuticals Inc (CPRX) Stock—What Could Drive It There?
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Hosted on MSN1d
Here's Why Momentum in Catalyst (CPRX) Should Keep going
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough ...
Benzinga.com1d
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Quotes, Forecast and News Summary
Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...
Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside Potential
Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...